ImmuPharma (LON:IMM) Shares Up 18.6% - Should You Buy?

Key Points

• ImmuPharma's stock price increased by 18.6%, reaching a high of GBX 13.45 ($0.18) during mid-day trading, a notable surge from its previous close of GBX 10.85 ($0.15).
• The company reported a net margin of 3,519.56% and a negative return on equity of 131.41%, with an expected earnings per share of -339.0000022 for the current fiscal year.
• ImmuPharma is a specialty biopharmaceutical company focused on developing peptide-based therapeutics, particularly for autoimmune diseases, with its lead program being P140 (Lupuzor™) for treating Lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price shot up 18.6% during mid-day trading on Friday . The stock traded as high as GBX 13.45 ($0.18) and last traded at GBX 12.87 ($0.17). 23,818,584 shares were traded during mid-day trading, an increase of 198% from the average session volume of 8,001,320 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Price Performance

The company has a 50-day simple moving average of GBX 2.88 and a 200-day simple moving average of GBX 2.86. The stock has a market cap of £64.31 million, a PE ratio of -1,446.07 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, equities analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.